NCT02987530View on ClinicalTrials.gov

National Multicenter Trial Evaluating Two Treatments in Patients with Primary Human Immunodeficiency Virus (HIV-1) Infection

PHASE3CompletedINTERVENTIONAL

Enrollment

101

Participants

Timeline

Start Date

April 11, 2017

Primary Completion Date

July 30, 2019

Study Completion Date

January 31, 2020

Conditions

HIV-1 Infection

Interventions

DRUG

Dolutegravir

Oral use, 50mg/day

DRUG

Darunavir-cobicistat

Oral use, 800-150mg/day

DRUG

Emtricitabine-Tenofovir

Oral use, Emtricititabine : 200mg/day Ténofovir : 245mg

Trial Locations (1)

Unknown

Hopital Bicetre, All the Regions of the Country (40 Centers)

All Listed Sponsors

collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

lead

ANRS, Emerging Infectious Diseases

OTHER_GOV

NCT02987530 - National Multicenter Trial Evaluating Two Treatments in Patients with Primary Human Immunodeficiency Virus (HIV-1) Infection | Biotech Hunter | Biotech Hunter